Hundreds of millions of SARS-CoV-2 mRNA-LNP vaccine doses have already been administered to humans. However, we lack a comprehensive understanding of the immune effects of this platform. The mRNA-LNP-based SARS-CoV-2 vaccine is highly inflammatory, and its synthetic ionizable lipid component responsible for the induction of inflammation has a long in vivo half-life. Since chronic inflammation can lead to immune exhaustion and non-responsiveness, we sought to determine the effects of pre-exposure to the mRNA-LNP on adaptive immune responses and innate immune fitness. We found that pre-exposure to mRNA-LNPs or LNP alone led to long-term inhibition of the adaptive immune responses, which could be overcome using standard adjuvants. On the other hand, we report that after pre-exposure to mRNA-LNPs, the resistance of mice to heterologous infections with influenza virus increased while Candida albicans decreased. The diminished resistance to Candida albicans correlated with a general decrease in blood neutrophil percentages. Interestingly, mice pre-exposed to the mRNA-LNP platform can pass down the acquired immune traits to their offspring, providing better protection against influenza. In summary, the mRNA-LNP vaccine platform induces long-term unexpected immunological changes affecting both adaptive immune responses and heterologous protection against infections. Thus, our studies highlight the need for more research to determine this platform’s true impact on human health.
- Many studies in mice have since found that the lipid nanoparticles (LNPs) claimed to be non-toxic and safe, are actually highly inflammatory and highly durable – lasting for a month in the body.
- The authors speculate that the resistance to influenza is not from strengthened immunity but is a product from an alternative pathway triggered by LNPs, and it’s unknown whether this resistance will apply to other infections. The reason for this is due to the fact the mice were more susceptible to fungal infections.
- There have been reports of COVID-19 vaccinated individuals developing rare fungal diseases and others with worsening of pre-existing fungal diseases.
- The mice getting the injections had lower neutrophils, the important and common first responder immune cells.
- The study also corroborated previous findings that the more shots, the greater the adverse reactions due to the lower T and B cell responses.
- The authors also found that if T progenitor cells were removed before the injection, and then returned after the injection, active T cell numbers were not reduced suggesting that the lipid nanoparticles directly reduce T progenitor cells and therefore the T cell response.
- The authors speculate that reduced immunity should not be permanent, but nobody truly knows.
- While the study showed that immunity could be passed onto offspring, particularly if both parents are immunized, the study did not address if the offspring also inherit immune weakness such as the decline in immunity against C. albicans.
- The increased rate of disease reported to VAERS after COVID injections, as well as many reports of emerging cancers also demonstrates reduced immunity in the “vaxxed.”
- 284 cases of breast cancer were reported after the COVID shots, while just 350 cases have been reported in the entire history of VAERS.
- 269 cases of leukemia were reported after the COVID shots, compared to 432 cases in the entire history of VAERS.
- 7,559 cases of shingles have been reported after the COVID shots when 28,180 cases have been reported following any vaccination – meaning around a quarter of cases occurred after the COVID shots. The CDC has indicated that a new case or recurrence of shingles primarily occurs in people with compromised immune systems and is a sign of weakened immunity. Source